Abbott Laboratories, a $20.4b global developer of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals is buying Cephea Valve Technologies, Inc, a developer of a less-invasive heart valve replacement technology for mitral valve disease. The deal Strengthens Abbott's in structural heart therapies. Cephea's artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of the diseased mitral valve restores normal blood flow through the heart. Mitral valve disease is the most common heart valve problem, affecting more than 4m people in the US. Abbott acquired Evalve, inc., a developer of leaky heart valves repair device. In 2015, It bought Tendyne Holdings, Inc, a developer of MIS devices for mitral valve replacement. In 2017, Abbott bought St. Jude Medical, for its structural heart disease treatment. Terms not announced.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers